Pharma Update

DNA Damage Response (DDR) Building a diversified and differentiated portfolio in DDR Camonsertib (ATR inhibitor) REPARE KSQ THERAPEUTICS KSQ-4279 (first-in-class USP1 inhibitor) . ATRi Stalled DNA replication fork ATR DNA double- strand breaks ATR is a key mediator of cellular DDR and is activated in response to DNA replication stress • Preclinical studies suggest camonsertib to be more selective and potent vs. other ATRi in development with best-in-class potential . • • Ongoing Phl/II (TRESR) demonstrated monotherapy responses in multiple tumors (ovarian, breast, prostate) including patients who received prior PARPI and prior platinum chemotherapy . • Currently investigated as monotherapy and in combo with various agents Ub RAD18 PCNA PCNA FANCD2 FANCI Fanconi Anemia (FA) complex detects and recruits ICL repair proteins FA Complex Ub FANCD2 (Ub FANCI XXXXX XXXXX USP1 USP1 Translesion synthesis Intra-strand Crosslink Repair USP1 is involved in DNA damage repair processes through mechanisms distinct from both PARPI and other targeted therapies KSQ-4279 is a first-in-class small molecule inhibitor of USP1 Combination with PARPi demonstrated strong activity in PARP naïve and PARP resistant mouse models Ph I trial in patients with advanced solid tumors ongoing Camonsertib in partnership with Repare Therapeutics; KSQ-4279 in partnership with KSQ Therapeutics; DDR-DNA Damage Response Roche 79

View entire presentation